REGE NEPHRO
Rege Nephro is a biotech company that specialized in R&D, production and marketing of renal disease therapeutics.
REGE NEPHRO
Industry:
Biotechnology Manufacturing Medical Rental
Founded:
2019-09-20
Address:
Kyoto, Kyoto, Japan
Country:
Japan
Website Url:
http://www.regenephro.co.jp
Status:
Active
Total Funding:
360 M JPY
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt WordPress Google Universal Analytics Wordpress Plugins Nginx
Similar Organizations
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Pilot Biotechnology
Pilot Biotechnology is an industrial biotechnology company engaged in the development, production, and sales of health care products.
Translate Bio
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Sinocelltech
Sinocelltech is a biotech company that develops and manufactures recombinant proteins, monoclonal antibodies, and vaccines.
Current Advisors List
Board_member
Current Employees Featured
Kenji Osafune Founder & Chief Scientific Advisor @ Rege Nephro
Founder & Chief Scientific Advisor
Katsuhisa Yamaguchi Member of the Board, CFO & General Manager of Finance & Administration Division @ Rege Nephro
Member of the Board, CFO & General Manager of Finance & Administration Division
Founder
Investors List
Kyoto University Innovation Capital
Kyoto University Innovation Capital investment in Series A - Rege Nephro
JAFCO
JAFCO investment in Series A - Rege Nephro
Fujifilm
Fujifilm investment in Series A - Rege Nephro
Japan Science and Technology Agency
Japan Science and Technology Agency investment in Series A - Rege Nephro
Kyogin Lease & Capital
Kyogin Lease & Capital investment in Series A - Rege Nephro
Official Site Inspections
http://www.regenephro.co.jp
- Host name: www500.sakura.ne.jp
- IP address: 59.106.13.150
- Location: Osaka Japan
- Latitude: 34.6848
- Longitude: 135.5142
- Timezone: Asia/Tokyo
- Postal: 543-0062
More informations about "Rege Nephro"
リジェネフロ株式会社
腎疾患に対する様々なソリューションを研究開発し、腎疾患に苦しむ患者さんのQuality of Lifeの改善により社会に貢献するSee details»
Rege Nephro Co., Ltd.
Our business was introduced in Science Japan, an online magazine published by JST. An article about Toshihiro Ishikiriyama, our president, was published in AnswersNews, serial column: …See details»
About Company – Rege Nephro Co., Ltd.
Rege Nephro Co., Ltd. Business R&D, production, and sales of therapeutic drugs for renal diseasesSee details»
Rege Nephro Co., Ltd. - J-Startup
Https://www.regenephro.co.jp/ Rege Nephro is a biotech company developing cell therapy for chronic kidney disease (CKD) and founded in 2019. There are 13 million patients with CKD in …See details»
Rege Nephro Co., Ltd. - LinkedIn
Rege Nephro is a clinical-stage biotech company developing cell therapy for chronic kidney disease (CKD) and small molecule for autosomal dominant polycystic kidney disease …See details»
Rege Nephro - Crunchbase Company Profile & Funding
Rege Nephro is a biotech company specializing in R&D, production, and marketing of renal disease therapeutics. It utilizes induced pluripotent stem cell (iPSC)-based technology from …See details»
Rege Nephro Co., Ltd. Successfully Completes Series B Funding to ...
Oct 8, 2024 · Rege Nephro Co., Ltd. is a clinical-stage biotech company utilizing induced pluripotent stem cell (iPSC)-based technology from the Center for iPS Cell Research and …See details»
Rege Nephro Co., Ltd. - BIO International Convention | BIO
Jun 6, 2023 · Rege Nephro is pre-clinical stage company developing a allogenic cell therapy by human iPS cell-derived nephron progenitor cells (iNPCs) for chronic kidney disease (CKD). …See details»
リジェネフロ株式会社の会社情報と資金調達 | NIKKEI COMPASS
リジェネフロ株式会社は、腎疾患に対するソリューションを研究開発する企業。 京都大学iPS細胞研究所（CiRA）の長船健二教授らが創業したスタートアップ。 ヒト由来のiPS細胞から腎 …See details»
COMPANY | Rege Nephro Co., Ltd.
Research and develop various solutions against kidney diseases,improve QOL among patients suffering from kidney diseases,and contribute to societySee details»
Rege Nephro Co., Ltd. Successfully Completes Series B Funding to ...
KYOTO, Japan, Oct. 7, 2024 /PRNewswire/ -- Rege Nephro Co., Ltd. (https://www.regenephro.co.jp/) is excited to announce that the company has successfully …See details»
Rege Nephro Company Profile 2024: Valuation, Funding
Developer of therapeutic drugs designed for patients suffering from renal failure.See details»
Mitsui Chemicals Invests in Clinical Kidney Disease Drug Developer …
Nov 5, 2024 · Rege Nephro is a clinical-stage drug discovery startup utilizing technology based on initial research from Professor OSAFUNE Kenji of Kyoto University’s Center for iPS Cell …See details»
リジェネフロ、ADPKD治療薬の前期第二相臨床試験の第2段階の …
May 27, 2024 · リジェネフロ株式会社 (https://www.regenephro.co.jp/) は、タミバロテンをADPKD治療薬開発品 (RN-014)とした前期第二相臨床試験の第2段階の被験者募集を4月より …See details»
会社情報 – リジェネフロ株式会社 - regenephro.co.jp
腎疾患に対する様々なソリューションを研究開発し、腎疾患に苦しむ患者さんのQuality of Lifeの改善により社会に貢献するSee details»
リジェネフロ、長船健二教授の研究グループが発見した常染色体 …
Dec 5, 2023 · リジェネフロ株式会社（本社：京都市左京区、代表取締役：森中紹文、以下「リジェネフロ」）は、この治療薬候補であるレチノイン酸受容体（RAR）作動薬を用いた臨床試 …See details»
/C O R R E C T I O N -- Rege Nephro CO., Ltd./ - Yahoo Finance
Oct 8, 2024 · Rege Nephro Co., Ltd. (https://www.regenephro.co.jp/) is excited to announce that the company has successfully developed a funding plan of total approximately 17 million dollar …See details»
Global Brain has invested in Rege Nephro Co., Ltd., a clinical-stage ...
Global Brain has decided to invest in Rege Nephro, based on its high regard for Rege Nephro’s business and talented management team with the ability to bring its plans to fruition. Global …See details»
Message from Representative Director – Rege Nephro Co., Ltd.
We are aiming at creating a global specialty pharmaceutical company focusing on R&D and production of renal regenerative medicine. Rege of RegeNephro means Regeneration. Since …See details»
Rege Nephro Co., Ltd. - VentureRadar
Develops cell therapy solutions for chronic kidney disease (CKD), leveraging nephron progenitor cells derived from iPS cells, founded in 2019.See details»